帕皮隆 - 莱弗勒综合征,对瑞桑基祖马布有很好的反应
Latifah Alibrahim1, Sarah Alrashid1, Majed Aleissa2
1Department of Dermatology, King Abdulaziz Medical City, Riyadh.
Dermatology reports
|February 27, 2026
概括
帕皮隆 - 莱弗勒综合征 (PLS) 的管理是具有挑战性的. 一名患有严重PLS皮肤问题的患者在其他治疗失败后,通过介素-23抑制剂risankizumab完全恢复.
科学领域:
- 皮肤病学 皮肤病学
- 遗传学 是一个遗传学.
- 免疫学 免疫学 免疫学
背景情况:
- 帕皮隆-莱弗勒综合征 (PLS) 是一种罕见的遗传疾病.
- PLS表现为棕植物角质皮肤病,皮肤病变和牙周病变.
- 由于治疗选择有限,管理PLS往往是困难的.
研究的目的:
- 报告一个严重的帕皮隆-莱弗勒综合征病例.
- 为了评估新生物疗法在治疗耐药的PLS病例中的疗效.
主要方法:
- 一个患有PLS的27岁女性的案例研究.
- 对患者对各种疗法的反应进行审查,包括局部药物,口服视网类药物和TNF抑制剂.
- 进行介素-23 抑制剂risankizumab的使用.
主要成果:
- 患者对之前的治疗反应不佳.
- 通过使用risankizumab.com实现了皮肤表现的完全解决.
- 在严重的PLS皮肤症状中,IL-23抑制被证明有效.
结论:
- 瑞桑基祖马布是对耐火性帕皮隆-莱弗勒综合征的潜在有效治疗方法.
- 准IL-23可能为PLS提供新的治疗途径.
- 需要进一步的研究来证实瑞桑基祖马布在PLS管理中的作用.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
604
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
658
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
658
